Sofosbuvir launch reverts to a decline - bet it'll come as a surprise to some of the analysts.
Warehoused patients will create a surge of demand during the first few quarters post launch which will tail off within a year. A decline should be expected in the U.S. without much concern over growth in other developed markets internationally.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.